enVVeno Medical Completes 1-for-35 Reverse Stock Split to Consolidate Shares
Summary
enVVeno Medical Corp. has completed a 1-for-35 reverse stock split, significantly reducing its outstanding shares and proportionally adjusting options and warrants.
Key Events
-
Reverse Stock Split Effected
Effective January 20, 2026, enVVeno Medical Corp. completed a one-for-thirty-five (1:35) reverse stock split of its common stock.
-
Share Count Significantly Reduced
The number of outstanding common shares was reduced from 22,946,223 to 655,606, with fractional shares rounded up to the nearest whole share.
-
Options and Warrants Adjusted
Outstanding stock options and warrants were proportionally adjusted, reducing the underlying shares by a factor of 35 and increasing exercise prices by the same factor.
-
Trading on Adjusted Basis
The company's common stock began trading on a reverse stock split-adjusted basis on Tuesday, January 20, 2026.
Analysis
enVVeno Medical Corp. has implemented a substantial 1-for-35 reverse stock split. This action, while not altering the company's fundamental value, is typically undertaken by companies with a low share price, often to meet exchange minimum bid requirements or improve stock optics. The significant consolidation ratio suggests considerable prior share price weakness, which can be perceived negatively by the market. Investors should monitor the stock's performance post-split and look for any accompanying strategic announcements that might justify the move beyond mere compliance.
At the time of this filing, NVNO was trading at $11.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $242M. The 52-week trading range was $10.54 to $196.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.